Royalty Pharma (RPRX) Total Debt (2019 - 2026)
Royalty Pharma (RPRX) posted Total Debt of $9.3 billion for Q1 2026, little changed sequentially from $9.3 billion in Q4 2025, and up 22.57% YoY from $7.6 billion in Q1 2025.
Royalty Pharma (RPRX) Total Debt (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Total Debt for 8 years, with the latest figure at $9.3 billion in Q1 2026.
- Quarterly Total Debt rose 22.57% year-over-year to $9.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 billion (up 22.57% YoY) and the FY2025 annual result came in at $9.3 billion, up 8.37% from the prior year.
- Total Debt was little changed at $9.3 billion in Q1 2026 per RPRX's latest filing, from $9.3 billion in the prior quarter.
- Over five years, Total Debt peaked at $9.3 billion in Q1 2026 and troughed at $6.1 billion in Q3 2023.
- A 5-year average of $7.7 billion and a median of $7.6 billion in 2024 frame the typical range for Total Debt.
- The widest YoY moves for Total Debt: up 40.34% in 2024, down 24.39% in 2024.
- Over 5 years, Total Debt stood at $7.1 billion in 2022, then slipped by 13.79% to $6.1 billion in 2023, then soared by 40.34% to $8.6 billion in 2024, then advanced by 8.37% to $9.3 billion in 2025, then gained by 0.06% to $9.3 billion in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $9.3 billion, $9.3 billion, and $8.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.34 Bn |
| Mar 31, 2026 | 9.34 Bn |
| Dec 31, 2025 | 9.33 Bn |
| Sep 30, 2025 | 8.95 Bn |
| Jun 30, 2025 | 8.00 Bn |
| Mar 31, 2025 | 7.62 Bn |
| Dec 31, 2024 | 8.61 Bn |
| Sep 30, 2024 | 7.61 Bn |
| Jun 30, 2024 | 7.60 Bn |
| Mar 31, 2024 | 6.14 Bn |
| Dec 31, 2023 | 6.14 Bn |
| Sep 30, 2023 | 6.13 Bn |
| Jun 30, 2023 | 7.13 Bn |
| Mar 31, 2023 | 8.12 Bn |
| Dec 31, 2022 | 7.12 Bn |
| Sep 30, 2022 | 8.11 Bn |
| Jun 30, 2022 | 7.22 Bn |
| Mar 31, 2022 | 7.22 Bn |
| Dec 31, 2021 | 7.20 Bn |
| Sep 30, 2021 | 7.21 Bn |